Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.21Last Year’s EPS
0.19Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -4.98%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted solid growth in certain segments such as Surgical Solutions and the expansion into the PRP market, along with increased EPS and reaffirmation of financial guidance. However, these positives were tempered by a decline in overall revenue, foreign currency losses, and challenges in the international segment.Company Guidance
During the Bioventus First Quarter 2025 Conference Call, the company provided financial guidance for the year, reiterating their expectations for full-year revenue growth between 6% to 8%, adjusted EBITDA ranging from $112 million to $116 million, and adjusted earnings per share (EPS) between $0.64 and $0.68. Despite a 4% revenue decline in Q1 due to divestiture effects, organic growth was 5%. The company reported first-quarter revenue of $124 million and adjusted earnings of $0.08 per share, reflecting a 33% increase. Bioventus maintains a strong outlook for the second half of 2025, anticipating an acceleration in growth driven by strategic initiatives across their business segments, particularly in Surgical Solutions and pain treatments. The company also highlighted plans to enhance profitability with an expected adjusted EBITDA margin expansion of at least 100 basis points for the year and aims to nearly double cash from operations compared to 2024, ultimately reducing net leverage below 2.5x by year-end.Strong Revenue Growth in Surgical Solutions
Surgical Solutions revenue grew by 7%, driven by strong double-digit growth in Ultrasonics with capital sales in the U.S. up by more than 50% compared to the prior year.
Successful Expansion in Pain Treatment Portfolio
Bioventus signed an agreement with APEX Biologix to be the exclusive distributor of their XCELL PRP system in the U.S. for orthopedics and sports medicine, marking their entry into the large and fast-growing PRP market.
Increased Earnings Per Share
Adjusted earnings of $0.08 per share increased by 33% compared to the prior year.
Reaffirmation of 2025 Financial Guidance
Bioventus reaffirmed its full-year financial guidance, including organic revenue growth of 6% to 8%, adjusted EBITDA of $112 million to $116 million, and EPS of $0.64 to $0.68.
---
BVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $7.03 | $6.20 | -11.81% |
Mar 11, 2025 | $8.76 | $10.80 | +23.29% |
Nov 05, 2024 | $13.71 | $11.48 | -16.27% |
Aug 06, 2024 | $6.26 | $8.09 | +29.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bioventus (BVS) report earnings?
Bioventus (BVS) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Bioventus (BVS) earnings time?
Bioventus (BVS) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVS EPS forecast?
BVS EPS forecast for the fiscal quarter 2025 (Q2) is 0.21.
---